Iron in Neurodegeneration - Cause or Consequence?

Overview

Journal Front Neurosci

Date 2019 Mar 19

PMID 30881284

Citations 122

Authors

Alain Ndayisaba

Christine Kaindlstorfer

Gregor K Wenning

Affiliations

Soon will be listed here.

Abstract

Iron dyshomeostasis can cause neuronal damage to iron-sensitive brain regions. Neurodegeneration with brain iron accumulation reflects a group of disorders caused by iron overload in the basal ganglia. High iron levels and iron related pathogenic triggers have also been implicated in sporadic neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and multiple system atrophy (MSA). Iron-induced dyshomeostasis within vulnerable brain regions is still insufficiently understood. Here, we summarize the modes of action by which iron might act as primary or secondary disease trigger in neurodegenerative disorders. In addition, available treatment options targeting brain iron dysregulation and the use of iron as biomarker in prodromal stages are critically discussed to address the question of cause or consequence.

Citing Articles

Major heme proteins hemoglobin and myoglobin with respect to their roles in oxidative stress - a brief review.

Sil R, Chakraborti A Front Chem. 2025; 13:1543455.

PMID: 40070406 PMC: 11893434. DOI: 10.3389/fchem.2025.1543455.

Diffusion tensor image analysis along the perivascular space and quantitative susceptibility mapping in the diagnosis and severity assessment of Parkinson's disease.

Ni C, Chen L, Lin R, Zheng W, Cai Y, Cai G Quant Imaging Med Surg. 2025; 15(2):1411-1424.

PMID: 39995711 PMC: 11847189. DOI: 10.21037/qims-24-1605.

Mitochondrial dysfunction, iron accumulation, lipid peroxidation, and inflammasome activation in cellular models derived from patients with multiple sclerosis.

Garcia-Salas R, Cilleros-Holgado P, Di Spirito A, Gomez-Fernandez D, Pinero-Perez R, Romero-Dominguez J Aging (Albany NY). 2025; 17(2):365-392.

PMID: 39918890 PMC: 11892916. DOI: 10.18632/aging.206198.

Neuroinflammation and iron metabolism after intracerebral hemorrhage: a glial cell perspective.

Ju J, Hang L Front Neurol. 2025; 15:1510039.

PMID: 39882361 PMC: 11774705. DOI: 10.3389/fneur.2024.1510039.

Iron Homeostasis Dysregulation, Oro-Gastrointestinal Microbial Inflammatory Factors, and Alzheimer's Disease: A Narrative Review.

Kuziak A, Heczko P, Pietrzyk A, Strus M Microorganisms. 2025; 13(1).

PMID: 39858890 PMC: 11767265. DOI: 10.3390/microorganisms13010122.

References

Fillebeen C, Mitchell V, Dexter D, Benaissa M, Beauvillain J, SPIK G . Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment. Brain Res Mol Brain Res. 1999; 72(2):183-94. DOI: 10.1016/s0169-328x(99)00221-1. View

Mirza B, Hadberg H, Thomsen P, Moos T . The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience. 2000; 95(2):425-32. DOI: 10.1016/s0306-4522(99)00455-8. View

Fleming R, Migas M, Holden C, Waheed A, Britton R, Tomatsu S . Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc Natl Acad Sci U S A. 2000; 97(5):2214-9. PMC: 15780. DOI: 10.1073/pnas.040548097. View

Moos T, Morgan E . Transferrin and transferrin receptor function in brain barrier systems. Cell Mol Neurobiol. 2000; 20(1):77-95. PMC: 11537550. DOI: 10.1023/a:1006948027674. View

Petrucelli L, Hardy J, Lee J, Farer M, Wolozin B . The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci. 2000; 20(16):6048-54. PMC: 6772599. View

Dhennin-Duthille I, Masson M, Damiens E, Fillebeen C, SPIK G, Mazurier J . Lactoferrin upregulates the expression of CD4 antigen through the stimulation of the mitogen-activated protein kinase in the human lymphoblastic T Jurkat cell line. J Cell Biochem. 2000; 79(4):583-93. View

Talpade D, Greene J, Higgins Jr D, Greenamyre J . In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone. J Neurochem. 2000; 75(6):2611-21. DOI: 10.1046/j.1471-4159.2000.0752611.x. View

Zecca L, Gallorini M, Schunemann V, Trautwein A, Gerlach M, Riederer P . Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem. 2001; 76(6):1766-73. DOI: 10.1046/j.1471-4159.2001.00186.x. View

Shaw K, Utsuki T, Rogers J, Yu Q, Sambamurti K, Brossi A . Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A. 2001; 98(13):7605-10. PMC: 34715. DOI: 10.1073/pnas.131152998. View

10.

Zhou B, Westaway S, Levinson B, Johnson M, Gitschier J, Hayflick S . A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet. 2001; 28(4):345-9. DOI: 10.1038/ng572. View

11.

Fillebeen C, Ruchoux M, Mitchell V, Vincent S, Benaissa M, Pierce A . Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. Brain Res Mol Brain Res. 2001; 96(1-2):103-13. DOI: 10.1016/s0169-328x(01)00216-9. View

12.

Torti F, Torti S . Regulation of ferritin genes and protein. Blood. 2002; 99(10):3505-16. DOI: 10.1182/blood.v99.10.3505. View

13.

Kress G, Dineley K, Reynolds I . The relationship between intracellular free iron and cell injury in cultured neurons, astrocytes, and oligodendrocytes. J Neurosci. 2002; 22(14):5848-55. PMC: 6757914. DOI: 20026601. View

14.

Yang F, Liu X, Quinones M, Melby P, Andrew Ghio , Haile D . Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation. J Biol Chem. 2002; 277(42):39786-91. DOI: 10.1074/jbc.M201485200. View

15.

Faucheux B, Martin M, Beaumont C, Hauw J, Agid Y, Hirsch E . Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem. 2003; 86(5):1142-8. DOI: 10.1046/j.1471-4159.2003.01923.x. View

16.

Dauer W, Przedborski S . Parkinson's disease: mechanisms and models. Neuron. 2003; 39(6):889-909. DOI: 10.1016/s0896-6273(03)00568-3. View

17.

Goodman L . Alzheimer's disease; a clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J Nerv Ment Dis. 1953; 118(2):97-130. View

18.

HALLGREN B, SOURANDER P . The effect of age on the non-haemin iron in the human brain. J Neurochem. 1958; 3(1):41-51. DOI: 10.1111/j.1471-4159.1958.tb12607.x. View

19.

Payton S, Cahill C, Randall J, Gullans S, Rogers J . Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol. J Mol Neurosci. 2003; 20(3):267-75. DOI: 10.1385/JMN:20:3:267. View

20.

Good P, Olanow C, Perl D . Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 1992; 593(2):343-6. DOI: 10.1016/0006-8993(92)91334-b. View